Antiangiogenic Agents in the Treatment of HER2-Negative Metastatic breast Cancer: A Brief Review

Publisher： Bentham Science Publishers

E-ISSN： 2211-5536|3|2|73-79

ISSN： 2211-5528

Source： Current Angiogenesis, Vol.3, Iss.2, 2014-07, pp. : 73-79

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001)

By Nishimura  

Molecular and Clinical Oncology, Vol. 1, Iss. 1, 2013-01 ,pp. : 47-52

Spandidos Publications

Access to resources Recommend Favorite

Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer

By Tozuka  

Molecular and Clinical Oncology, Vol. 1, Iss. 1, 2013-01 ,pp. : 93-99

Spandidos Publications

Access to resources Recommend Favorite

Metastatic breast cancer in patients with schizophrenia

By Meyer Aaron A.  

Molecular and Clinical Oncology, Vol. 1, Iss. 2, 2013-01 ,pp. : 359-364

Spandidos Publications

Access to resources Recommend Favorite

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium

By  

The Journal Of Pathology: Clinical Research, Vol. 1, Iss. 1, 2015-02 ,pp. : 18-32

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more

By Kontani  

Molecular and Clinical Oncology, Vol. 1, Iss. 2, 2013-01 ,pp. : 225-230

Spandidos Publications

Access to resources Recommend Favorite